Search MGRX
MANGOCEUTICALS, INC.
Nasdaq · CIK 1938046
Last close0.44
Daily change-0.04 (-9.15%)
10 Years gain-99.27%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
MGRX · STANDARD
SIC 8090 · Services-Misc Health & Allied Services, NEC · Fiscal year end 1231
Fundamental
31.4Momentum
0.0Acceleration
22.4Confidence
69.0Annual Revenue4
Quarterly Revenue13
Annual CFO4
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.3 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
ROIC expansionROIC improved by 1.1983 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 2.6156 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 2370.9478 percentage points.
Heavy share dilution · HIGHDiluted share count increased 272.7278%.
Key Metrics
Revenue Growth TTM-23.89%OK
Revenue CAGR 3Y270.88%OK
Gross Margin55.03%OK
Operating Margin-4,362.94%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-82.57%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y272.73%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $456,021.00 | $250,386.00 | -$18.03M | -$5.85M | n/a | 54.91% | -3,954.28% | n/a | -103.22% | 10.07M |
| 2025 FY Dec 31, 2024 | $615,873.00 | $379,964.00 | -$7.97M | -$4.86M | n/a | 61.7% | -1,294.42% | n/a | -90.47% | 1.98M |
| 2024 FY Dec 31, 2023 | $731,493.00 | $431,501.00 | -$9.22M | -$7.00M | -$7.00M | 58.99% | -1,260.28% | -957.07% | n/a | 1.07M |
| 2023 FY Dec 31, 2022 | $8,939.00 | $4,850.00 | -$1.99M | -$1.35M | -$1.39M | 54.26% | -22,279.7% | -15,545.59% | n/a | 10.8M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $388,976.00 | sum latest 4 fiscal quarters Revenue | OK | 0001493152-26-037873, 0001493152-25-023640 |
| Revenue Growth TTM | -23.89% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-26-037873, 0001493152-25-023640 |
| Revenue CAGR 3Y | 270.88% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-014478 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001493152-26-014478 |
| Gross Profit CAGR 3Y | 272.35% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001493152-26-014478 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-26-037873, 0001493152-25-023640 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 55.03% | Gross Profit / Revenue | OK | 0001493152-26-037873, 0001493152-25-023640 |
| Operating Margin | -4,362.94% | Operating Income / Revenue | OK | 0001493152-26-037873, 0001493152-25-023640 |
| ROIC | -82.57% | NOPAT / Average Invested Capital | OK | 0001493152-26-037873, 0001493152-25-023640 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001493152-26-037873 |
| Current Ratio | 0.18x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.02 | Revenue / Diluted Shares | OK | 0001493152-26-037873, 0001493152-25-023640 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |